CD274 and non-small cell lung carcinoma: IS-IC is revealed as powerful predictive biomarker for response to combination immunotherapy in metastatic CRC patients, enrolled in phase II AtezoTRIBE clinical trial [30] and for response to anti-PDL-1 immunotherapy in non-small cell lung cancer (NSCLC) [32,55].